Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer-Reference-Cited by-同舟云学术

Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer

Published:2005-06 Issue:16_suppl Volume:23 Page:3004-3004
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Blackwell K. L.¹,Burstein H.¹,Pegram M.¹,Storniolo A. M.¹,Salazar V. M.¹,Maleski J. E.¹,Lin X.¹,Spector N.¹,Stein S. H.¹,Berger M. S.¹

Affiliation:

1. Duke Univ Medcl Ctr, Durham, NC; Dana-Farber Cancer Inst, Boston, MA; Univ of CA, Los Angeles, Los Angeles, CA; Indiana Univ Cancer Ctr, Indianapolis, IN; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Research Triangle Park, NC

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.3004

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment augmenter la performance des médicaments anti-HER?;Cancer du sein;2012

2. Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation;Critical Reviews in Oncology/Hematology;2011-06

3. LAPATINIB IN BREAST CANCER - THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT;Biomedical Papers;2010-12-01

4. Antiangiogenic strategies in breast cancer management;Critical Reviews in Oncology/Hematology;2010-10

5. Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer;Journal of Clinical Oncology;2010-07-10